Preclinical Oncology Models for Translational Research

Xenograft.org provides a centralized resource for industry and academic teams seeking rigorously validated in vivo cancer models. Our platform consolidates Cell-Line–Derived Xenograft (CDX) models, Patient-Derived Xenograft (PDX) models, syngeneic mouse models, and humanized (HSC and PBMC) systems, enabling efficient comparison and selection across major solid tumor and hematologic malignancies.

Each model page includes biological background, growth kinetics, available molecular data, and study-ready configurations to streamline the design of your in vivo efficacy or pharmacology program.

Explore Cancer Models by Type

Easily navigate through curated collections of xenograft and immuno-oncology models. Select a cancer indication below to view available models, supporting datasets, and study options.

• Solid Tumor CDX Models

Well-established human cell–line xenografts spanning major solid tumor types, optimized for reproducible tumor take rates, consistent growth kinetics, and streamlined study initiation to support robust efficacy and pharmacology assessments.

• Patient-Derived Xenografts (PDX)

A growing library of more than 200 clinically annotated PDX models that preserve patient-specific tumor biology, enabling translational studies and biomarker-driven strategies.

• Syngeneic Mouse Models

Murine tumor models compatible with fully immunocompetent hosts, supporting evaluation of checkpoint inhibitors, T cell–engaging therapeutics, innate immunity modulators, and combination regimens.

• Humanized HSC and PBMC Models

Immune-reconstituted NSG-based platforms allowing assessment of human immune responses, T-cell–dependent therapies, IO agents, and CAR-T efficacy in vivo.